Last updated: 11/07/2018 18:53:06

Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart

Request patient level data
GSK study ID
SB 480848/035
See study documents
Clinicaltrials.gov ID
NCT00411073
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A Study to Evaluate the Effect of Repeat Oral Doses of Darapladib on Cardiac Conduction as Compared to Placebo and a Single Oral Dose of Moxifloxacin
Trial description: This is a study to assess the effects of darapladib on the cardiac conduction of the heart as compared to placebo and moxifloxacin. This a four period crossover design with each period lasting about 10 days. There will be a 7 to 10 day wash out in between each period.
Primary purpose:
Treatment
Trial design:
Crossover Assignment
Masking:
Not applicable
Allocation:
Randomized
Primary outcomes:

Change in QTc interval as compared to placebo and moxifloxacin

Timeframe: throughout the study

Secondary outcomes:

Change in ECG parameters as compared to placebo and moxifloxacin

Timeframe: throughout the study

Interventions:
  • Drug: Darapladib
    • Enrollment:
    72
    Primary completion date:
    Not applicable
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Not applicable
    Medical condition
    Atherosclerosis
    Product
    darapladib
    Collaborators
    Not applicable
    Study date(s)
    December 2006 to June 2007
    Type
    Interventional
    Phase
    1

    Participation criteria

    Sex
    Female & Male
    Age
    18 - 65 years
    Accepts healthy volunteers
    Yes
    • Healthy
    • Body weight greater than 50 kg (110 lbs) and a body mass index between 19 and 30
    • cardiac abnormalities
    • history of asthma or severe allergic reactions
    Inclusion and exclusion criteria
    Inclusion criteria:
    • Healthy
    • Body weight greater than 50 kg (110 lbs) and a body mass index between 19 and 30
    • Signed and dated written informed consent prior to admission to the study
    • Subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions
    Exclusion criteria:
    • cardiac abnormalities
    • history of asthma or severe allergic reactions
    • history of alcohol or drug abuse
    • use of prescription or non-prescription drugs or vitamins or herbal supplements
    • history of cholecystectomy or biliary tract disease
    • pregnant or nursing women
    • history of allergy to the study drugs

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    Evansville, Indiana, United States, 47714
    Status
    Study Complete
    Contact us

    Study documents

    Clinical study report
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Refer to study documents

    Recruitment status
    Study complete
    Actual primary completion date
    Not applicable
    Actual study completion date
    2007-24-06

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Participate in clinical trial
    Additional information
    Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
    Click here
    Access to clinical trial data by researchers
    Visit website